Advertisement

Advertisement

Leukemia

Fixed-Dose, First-Line Ibrutinib/Venetoclax Combination Achieves Durable Remissions in CLL

The combination of fixed-duration, first-line treatment with ibrutinib plus venetoclax achieved complete responses in more than half of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), based on the primary analysis of the fixed-dose cohort of the phase II CAPTIVATE ...

Leukemia

ELEVATE-RR Trial: Acalabrutinib as Effective as Ibrutinib, With Fewer Cardiac Effects, in Resistant CLL

Acalabrutinib was equally efficacious with less toxicity when compared directly with ibrutinib in patients with previously treated relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of an open-label, randomized, noninferiority phase III trial presented at the 2021...

leukemia

Curtis Lachowiez, MD, on AML: Venetoclax Combined With FLAG-IDA

Curtis Lachowiez, MD, of The University of Texas MD Anderson Cancer Center, discusses data that show combining venetoclax with FLAG-IDA chemotherapy to treat patients with newly diagnosed acute myeloid leukemia led to minimal residual disease negativity in more than 90% of those achieving a composite complete response (Abstract AML-024).

Leukemia
Immunotherapy

AUTO1: CAR T-Cell Product for Adult Patients With Relapsed or Refractory B-Cell ALL

In a phase I trial (ALLCAR19) reported in the Journal of Clinical Oncology, Roddie et al found that the fast off-rate autologous CD19 chimeric antigen receptor (CAR) T-cell therapy CAT19-41BB-Z—also known as AUTO1—was well tolerated and produced high remission rates in adults with relapsed or...

Leukemia

ELEVATE-RR Trial: Acalabrutinib as Effective as Ibrutinib, With Fewer Cardiac Effects, in Resistant CLL

Acalabrutinib was equally efficacious with less toxicity when compared directly with ibrutinib in patients with previously treated relapsed or refractory chronic lymphocytic leukemia (CLL), according to the results of an open-label, randomized, noninferiority phase III trial presented at the 2021...

Leukemia
Issues in Oncology

Ibrutinib and Cardiovascular Risk in Patients With Chronic Lymphocytic Leukemia

In a Canadian population-based cohort study reported in the Journal of Clinical Oncology, Abdel-Qadir et al found that ibrutinib treatment for chronic lymphocytic leukemia (CLL) is associated with increased risks of atrial fibrillation, bleeding, and heart failure, but not ischemic stroke or acute...

Leukemia
Issues in Oncology

Study Suggests Demographic Enrollment Reporting Requirements for Acute Leukemia Clinical Trials Are Lacking

Requirements instituted to address racial and ethnic disparities in clinical trial enrollment did not lead to increased inclusion of Black and Hispanic participants in clinical acute leukemia research, according to a new study published by Andrew Hantel, MD, and colleagues in the journal Blood...

Leukemia
Genomics/Genetics

Effect of Concurrent Focal 22q11.22 Deletions and IKZF1 Alterations on Outcomes in Pediatric Patients With B-Cell ALL

In a study reported in JAMA Oncology, Mangum et al found that focal deletions in chromosome 22q11.22 were associated with poor outcomes in pediatric patients with B-cell acute lymphoblastic leukemia (ALL) with IKZF1 alterations. As stated by the investigators, “Alterations in the IKZF1 gene drive...

Leukemia
Lymphoma
COVID-19

Study Explores Relationship Between Anti-CD20 Therapy and Reduced Responses to mRNA COVID-19 Vaccines

Patients with lymphoma or other lymphoid cancers should continue to take steps to protect themselves from COVID-19 even if they have been vaccinated against the disease, a new study by Jennifer Crombie, MD, and colleagues published in Blood Advances suggests. The study found that patients who had...

Leukemia
Immunotherapy

Outcomes Notably Improving for Adult ALL

Outcomes in adults with acute lymphoblastic leukemia (ALL) are almost rivaling those in pediatric ALL, thanks to the benefits achieved by incorporating blinatumomab and inotuzumab into chemotherapy regimens. New ways of administering the chemotherapy component are also increasing tolerability and...

Leukemia
Genomics/Genetics

Study Identifies Possible New Genetic Biomarkers of Pediatric Leukemia

In a study published by Magnum et al in JAMA Oncology, researchers reported on how two separate DNA changes appear to predict aggressive childhood leukemias when they occur in combination. The team evaluated tumor characteristics of more than 1,300 pediatric patients with B-cell acute lymphoblastic ...

Leukemia
Immunotherapy

Donor-Derived CD7 CAR T Cells May Lead to Remissions in Patients With Relapsed or Refractory T-ALL

In a Chinese single-institution phase I study reported in the Journal of Clinical Oncology, Pan et al found that donor-derived CD7 chimeric antigen receptor (CAR) T-cell therapy produced a high complete remission rate in patients with relapsed or refractory T-cell acute lymphoblastic leukemia...

Leukemia
Immunotherapy

Experimental Small-Molecule Inhibitor May Improve Responses to Cellular Therapies in Advanced CLL

Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T-cell therapy to do its job. Now, a new study from researchers at the Perelman School of...

hematologic malignancies
leukemia
immunotherapy

Alexey V. Danilov, MD, PhD, on Lymphoid Malignancies: Novel Agents Targeting BTK Inhibitor–Resistant Disease

Alexey V. Danilov, MD, PhD, of City of Hope, discusses the uses and side effects of cellular and immune therapies, including venetoclax and obinutuzumab, which may prove to be effective in treating highly resistant lymphoid malignancies such as chronic lymphocytic leukemia.

Leukemia
Skin Cancer
Gynecologic Cancers
Kidney Cancer
Lung Cancer
Thyroid Cancer
Immunotherapy

FDA Pipeline: Reviews for Agents in Lung Cancer, Thyroid Cancer, Kidney Cancer, and More

Recently, the U.S. Food and Drug Administration (FDA) accepted applications for agents aiming to treat non–small cell lung cancer (NSCLC), differentiated thyroid cancer, renal cell carcinoma (RCC), hypersensitive acute lymphoblastic leukemia (ALL), mucosal melanoma, and endometrial carcinoma....

Leukemia
Lymphoma

Asparaginase Erwinia Chrysanthemi (Recombinant)-rywn for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

On June 30, 2021, asparaginase erwinia chrysanthemi (recombinant)-rywn was approved as a component of a multiagent chemotherapeutic regimen for treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adult and pediatric patients 1 month or older who have developed...

Leukemia
Lymphoma

Expert Point of View: Jacqueline C. Barrientos, MD, MS

The ASCO Post invited Jacqueline C. Barrientos, MD, MS, Associate Professor of Medicine, CLL Research and Treatment Program, Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, to comment on the ALPINE findings presented at the European Hematology Association (EHA) Virtual...

Lymphoma
Leukemia

Zanubrutinib Superior to Ibrutinib for CLL/SLL in Phase III ALPINE Trial

Zanubrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, significantly improved response rates and delayed disease progression as compared with the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...

Leukemia

ELEVATE-RR Trial: Acalabrutinib vs Ibrutinib in Previously Treated Patients With CLL

As reported in the Journal of Clinical Oncology by John C. Byrd, MD, and colleagues, the phase III ELEVATE-RR trial has shown noninferior progression-free survival with the more selective Bruton’s tyrosine kinase (BTK) inhibitor acalabrutinib vs the less selective inhibitor ibrutinib in previously...

Leukemia

Expert Point of View: Guru Subramanian Guru Murthy

Invited discussant Guru Subramanian Guru Murthy, MD, MS, of the Medical College of Wisconsin, Milwaukee, commented on the study of aspacytarabine in the first-line therapy for patients with acute myeloid leukemia (AML) unfit for standard chemotherapy. “This study elegantly highlights there is still ...

Leukemia

Study Finds Cytarabine Prodrug Active and Safe in Older Compromised Patients With AML

Aspacytarabine, a cytarabine prodrug, was reported to be safe and effective as first-line therapy for patients with acute myeloid leukemia (AML) who were unfit for intensive induction chemotherapy, according to the results of a phase II study presented during the 2021 ASCO Annual Meeting.1 The...

Leukemia

Pulsed Vincristine/Dexamethasone Maintenance in Pediatric Acute Lymphoblastic Leukemia

In a Chinese phase III trial (CCCG-ALL-2015) reported in The Lancet Oncology, Yang et al found that 1 year of maintenance therapy with pulsed vincristine and dexamethasone was noninferior to 2 years in low-risk pediatric patients with acute lymphoblastic leukemia and was borderline inferior in...

Leukemia
Genomics/Genetics

Can Treatment With Thiopurines Induce Mutations That May Lead to Pediatric Leukemia Relapse?

Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers. Now, a research team has shown how thiopurines may lead to mutations that set patients up for disease relapse. These findings were published by Yang et al in Nature Cancer. The research...

Leukemia

B-Cell Acute Lymphoblastic Leukemia: Update on Clinical Trials

“Learning never exhausts the mind.” —Leonardo da Vinci To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on treatments under study ...

Leukemia

Phase III GLOW Trial: Improved Outcomes With First-Line Ibrutinib Plus Venetoclax in Elderly Patients With CLL

Fixed-duration ibrutinib and venetoclax as a first-line treatment yielded superior outcomes compared with chlorambucil plus obinutuzumab in patients with chronic lymphocytic leukemia (CLL), based on the primary analysis of the phase III GLOW trial presented during the European Hematology...

Leukemia
Immunotherapy

Combination Ficlatuzumab and Cytarabine Show Clinical Activity in Relapsed/Refractory AML

Despite advances in the treatment of acute myeloid leukemia (AML), only 29.5% of patients with the cancer are alive 5 years after diagnosis. Even with aggressive therapy, just 30% of patients achieve a complete remission with a median survival of 7.5 months, making it imperative to develop novel...

Leukemia

Calaspargase Pegol vs Pegaspargase in Pediatric ALL

In a phase III trial (DFCI 11-001) reported in the Journal of Clinical Oncology, Vrooman et al found that the novel pegylated asparaginase formulation calaspargase pegol (calaspargase) given every 3 weeks was associated with similar serum asparaginase activity nadir values, survival outcomes, and...

Leukemia

Being Both a Cancer Provider and a Cancer Survivor Is a Rare Privilege

Perhaps my 35-year career as a surgical oncologist and researcher specializing in soft-tissue sarcomas should have prepared me to recognize the signs of chronic lymphocytic leukemia (CLL) when they first appeared a few days before Christmas in 2016, but it did not. In fact, my symptoms were so...

Leukemia

Expert Point of View: Jacqueline C. Barrientos, MD

The invited discussant of the phase I trial of lisaftoclax (APG-2575), Jacqueline C. Barrientos, MD, of Hofstra/Northwell, Great Neck, New York, commented on the positive findings: “The 15 patients with chronic lymphocytic leukemia [CLL] had an objective response rate of 80% and a median time to...

Leukemia

Novel BCL2 Inhibitor Shows Activity in CLL in Phase I Trial

The novel, selective BCL2 inhibitor lisaftoclax (APG-2575) has shown activity in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) in a phase I study reported at the 2021 ASCO Annual Meeting.1 Preliminary data suggest that lisaftoclax stands out for its favorable safety...

Leukemia
Lymphoma

Expert Point of View: Jacqueline C. Barrientos, MD, MS

Invited discussant Jacqueline C. Barrientos, MD, MS, of Northwell Health Cancer Institute, Zucker School of Medicine at Hofstra/Northwell in Great Neck, New York, noted that, although both ibrutinib and venetoclax have shown superior results to chemotherapy, each drug is associated with toxicity....

Lymphoma
Leukemia

Fixed-Dose, First-Line Ibrutinib/Venetoclax Combination Achieves Durable Remissions in CLL

The combination of fixed-duration, first-line treatment with ibrutinib plus venetoclax achieved complete responses in more than half of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL), based on the primary analysis of the fixed-dose cohort of the phase II CAPTIVATE ...

Leukemia

Arsenic Plus All-Trans Retinoic Acid for Pediatric Patients With Acute Promyelocytic Leukemia

In a Chinese study (CCLG-APL2016) reported in the Journal of Clinical Oncology, Zheng et al found that the combination of arsenic with all-trans retinoic acid (ATRA) was associated with good survival outcomes in pediatric patients with acute promyelocytic leukemia. Study Details The multicenter...

Leukemia
Immunotherapy

Humanized CD19-Targeted CAR T-Cell Treatment in Patients With Relapsed or Refractory B-Cell ALL

In a pilot study reported by Myers et al in the Journal of Clinical Oncology, a humanized CD19-targeted chimeric antigen receptor (CAR) T-cell product developed by the investigators (huCART19) was found to produce durable remissions and prolonged CAR T-cell persistence in CAR-naive and CAR-exposed...

Leukemia

Effect of Myeloid Progenitor Cell Product on the Risk of Infection During Induction Chemotherapy for AML

In a phase II trial reported in the Journal of Clinical Oncology, Desai et al found that the addition of the myeloid progenitor cell product romyelocel-L to granulocyte colony-stimulating factor (G-CSF) reduced the incidence of infection and antimicrobial use vs G-CSF alone during induction...

Leukemia

Lessons From Pneumococcal Vaccine Responses in Patients With CLL in an Evolving Vaccine Landscape

The role of vaccines in mitigating the significant morbidity and mortality associated with infections in chronic lymphocytic leukemia (CLL) is a developing field of study, punctuated by the advent of novel therapeutic agents and pressing questions regarding the global SARS–CoV-2 vaccination...

Leukemia

Low Response Rates to Conjugate Pneumococcal Vaccine in Patients With Chronic Lymphocytic Leukemia

In an Italian study reported in Leukemia, Francesca Romana Mauro, MD, of the Department of Translational and Precision Medicine, Sapienza University, Rome, and colleagues found that only a small minority of patients with chronic lymphocytic leukemia (CLL) developed an adequate immune response to...

multiple myeloma
leukemia

Martin Kaiser, MD, on Myeloma and Plasma Cell Leukemia: Transplantation Plus Daratumumab/CVRD Therapy

Martin Kaiser, MD, of The Institute of Cancer Research and Royal Marsden Hospital, discusses findings from the UK OPTIMUM/MUKNINE trial on the depth of response and minimal residual disease status in patients with ultra-high–risk newly diagnosed multiple myeloma and plasma cell leukemia who were treated with augmented autologous transplant and daratumumab plus cyclophosphamide, bortezomib, lenalidomide, and dexamethasone (Abstract S181).

leukemia
immunotherapy

Bijal D. Shah, MD, on CLL: CAR T-Cell Therapy With Brexucabtagene Autoleucel

Bijal D. Shah, MD, of the H. Lee Moffitt Cancer Center, discusses phase II results of the ZUMA-3 study, which evaluated brexucabtagene autoleucel (KTE-X19), an anti-CD19 CAR T-cell therapy, in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (Abstract 7002).

leukemia
lymphoma

Paolo Ghia, MD, PhD, on CLL/SLL and Ibrutinib Plus Venetoclax: A Primary Analysis of the CAPTIVATE Trial

Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, discusses phase II results from the CAPTIVATE study, which examined ibrutinib plus venetoclax as a fixed-duration first-line treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7501).

Leukemia
Immunotherapy

Brexucabtagene Autoleucel in Adults With Relapsed or Refractory B-Cell ALL: ZUMA-3

As reported in The Lancet by Shah et al, the pivotal phase II ZUMA-3 trial has shown a high rate of complete remission with the autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (formerly KTE-X19) in adults with relapsed or refractory B-cell acute...

Issues in Oncology
Lymphoma
Leukemia
Kidney Cancer
CNS Cancers

Study Explores Incidence Rates for Various Pediatric Cancers Across Age and Racial Groups

New research has uncovered substantial differences in the rates of childhood cancers when considering a single year of age rather than grouping several years together. The study, published by Marcotte et al in the journal Cancer, also found that minority children seem to have different risks than...

Leukemia
Lymphoma

Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Older Patients With CLL/SLL

In a primary analysis of the phase III GLOW study, a once-daily, all-oral, fixed-duration dose of ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) resulted in superior progression-free survival than treatment with chlorambucil and obinutuzumab. Arnon...

leukemia

Arnon P. Kater, MD, PhD, on CLL: Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab

Arnon P. Kater, MD, PhD, of the University of Amsterdam, discusses a primary analysis of the phase III GLOW study, which, for the first time, compared the efficacy and safety of fixed-duration ibrutinib plus venetoclax with chlorambucil plus obinutuzumab for first-line treatment of older patients with chronic lymphocytic leukemia (LB1902).

leukemia

Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response

Keith W. Pratz, MD, of the University of Pennsylvania, discusses the outcomes of patients with acute myeloid leukemia who took part in the VIALE-A trial and were treated with venetoclax and azacitidine. The patients had achieved both composite complete remission and measurable residual disease of < 10-3 (Abstract S137).

Leukemia
Lymphoma

Zanubrutinib vs Ibrutinib in Relapsed/Refractory CLL/SLL: ALPINE Trial

Zanubrutinib—a second-generation Bruton's tyrosine kinase (BTK) inhibitor—significantly improved response rates and delayed disease progression as compared to the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...

Leukemia
Genomics/Genetics

Addition of Gemtuzumab Ozogamicin to Conventional Background Chemotherapy in Pediatric Patients With KMT2A-Rearranged AML

As reported in the Journal of Clinical Oncology by Pollard et al, a subgroup of pediatric patients with KMT2A-rearranged acute myeloid leukemia (AML) in the phase III Children’s Oncology Group AAML0531 trial had improved outcomes with the addition of the CD33-targeting agent gemtuzumab ozogamicin...

leukemia
immunotherapy

Nicholas J. Short, MD, on ALL: Ponatinib Plus Blinatumomab May Help Patients Avoid Transplants

Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses early results from a phase II study which showed that combining ponatinib and blinatumomab in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia may prove to be an effective chemotherapy-free regimen that might reduce the need for allogeneic hematopoietic stem cell transplant (Abstract 7001).

Leukemia

Venetoclax Plus FLAG-IDA Induction and Consolidation for AML

In a single-institution phase I/II study reported in the Journal of Clinical Oncology, Courtney D. DiNardo, MD, and colleagues found that the combination of venetoclax with FLAG-IDA (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin) in induction and consolidation...

Leukemia

Ibrutinib/Venetoclax Provides Durable Remission for Patients With Newly Diagnosed CLL

The combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL). Findings from a single-institution phase II study were published by Nitin Jain, MD, and colleagues in JAMA Oncology and provide the longest ...

Advertisement

Advertisement

Advertisement